BerGenBio ASA (FRA:7BG0)

€ 0.708 0.009 (1.29%) Market Cap: 28.14 Mil Enterprise Value: 13.42 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 58/100

Q3 2024 Bergenbio ASA Earnings Call Transcript
Nov 13, 2024

€0.538 (-11.22%)

Earnings
Q2 2024 Bergenbio ASA Earnings Call Transcript
Aug 21, 2024

€0.924 (-5.42%)

Earnings
Q1 2024 Bergenbio ASA Earnings Call Transcript
May 29, 2024

€1.11 (-1.77%)

Earnings
Q3 2023 Bergenbio ASA Earnings Call Transcript
Nov 14, 2023

€1.4 (+0.72%)

Earnings
Q2 2023 Bergenbio ASA Earnings Call Transcript
Aug 23, 2023

€0.83 (-11.70%)

Earnings
Q4 2022 Bergenbio ASA Earnings Call Transcript
Feb 16, 2023

€35.01 (+2.28%)

Earnings
Q3 2022 Bergenbio ASA Earnings Call Transcript
Nov 15, 2022

€40.05 (-0.87%)

Earnings
Q2 2022 Bergenbio ASA Earnings Call Transcript
Aug 23, 2022

€66.9 (-4.02%)

Earnings
Q1 2022 Bergenbio ASA Earnings Call Transcript
May 24, 2022

€82.73 (-3.27%)

Earnings
Bergenbio ASA Strategy Update Transcript
May 04, 2022
Q4 2021 Bergenbio ASA Earnings Call Transcript
Feb 16, 2022

€95.07 (+1.32%)

Earnings
Q3 2021 Bergenbio ASA Earnings Call Transcript
Nov 16, 2021

€109.23 (+2.37%)

Earnings
Q2 2021 Bergenbio ASA Earnings Call Transcript
Aug 17, 2021

€113.33 (-5.99%)

Earnings
Q1 2021 Bergenbio ASA Earnings Call Transcript
May 19, 2021

€122.05 (-11.00%)

Earnings
Bergenbio ASA to Discuss Top Line Data From Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients Call Transcript
May 18, 2021
Q4 2020 Bergenbio ASA Earnings Call Transcript
Feb 10, 2021

€187.17 (-0.43%)

Earnings
Q3 2020 Bergenbio ASA Earnings Call Transcript
Nov 17, 2020

€138.16 (-4.11%)

Earnings
Q2 2020 Bergenbio ASA Earnings Call Transcript
Aug 18, 2020

€175.86 (-2.54%)

Earnings
Q1 2020 Bergenbio ASA Earnings Call Transcript
May 19, 2020

€200.91 (-5.57%)

Earnings
Q4 2019 Bergenbio ASA Earnings Call Transcript
Feb 11, 2020

€97.42 (+8.39%)

Earnings

Q1 2022 Bergenbio ASA Earnings Call Transcript

May 24, 2022 / 08:00AM GMT

Release Date Price: €82.73 (-3.27%)

Transcript

Operator

Ladies and gentlemen, welcome to the BerGenBio Q1 2022 Conference Call. (Operator Instructions) This conference is being recorded.

I will now hand it over to the speakers. Please begin.

Martin Olin

BerGenBio ASA - CEO

Thank you very much for the introduction. Good morning. I'm Martin Olin, the CEO of BerGenBio. I'm very pleased to present to you with our Q1 highlights and financials for the first quarter. I'll just remind everyone about the forward-looking statements.

So this is a snapshot of BerGenBio. BerGenBio is a world leader in exploring (inaudible) transformative treatment modality for severe diseases. The development focus going forward will be focused on bemcentinib, our lead program, which has been dosed in more than 600 patients as of today, approximately 400 in oncology and 200 in COVID. And we are moving bemcentinib forward in 2 significant indications: One, a biomarker-driven population in first-line non-small cell lung cancer, which is carrying or harboring a mutation in the STK11 gene.

The second opportunity we're

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.